FDA approves NPS Pharmaceuticals' (NPSP) Gattex
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NPS Pharma (NPSP) Establishes Distribution Network for Gattex
December 27, 2012 8:06 AM ESTNPS Pharmaceuticals, Inc. (Nasdaq: NPSP) has established a patient-centric distribution and clinical service network for Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use. The network is comprised of leading specialty home infusion providers, including Accredo Health Group, Inc.; BioScrip; Inc.; Coram, LLC; ThriveRx; and... More
Cramer Makes Solid Call on NPS Pharma (NPSP) into Gattex PDUFA
December 21, 2012 1:05 PM ESTNPS Pharmaceuticals (Nasdaq: NPSP) is back in positive territory today following some volatility earlier on an announcement that it received FDA approval for its Gattex (Teduglutide [rDNA origin]) for Injection. The drug will be approved for subcutaneous use for the treatment of adult... More
NPS Pharma (NPSP) Receives FDA Approval for Gattex
December 21, 2012 12:11 PM ESTNPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced that the U.S. Food and Drug Administration (FDA) has approved Gattex (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.... More
